<SEC-DOCUMENT>0000200406-12-000123.txt : 20120806
<SEC-HEADER>0000200406-12-000123.hdr.sgml : 20120806
<ACCEPTANCE-DATETIME>20120806172151
ACCESSION NUMBER:		0000200406-12-000123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120806
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120806
DATE AS OF CHANGE:		20120806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1212

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		121010647

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201208068-kbapineuzumab.htm
<DESCRIPTION>2012 0806 8-K BAPINEUZUMAB IV
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings e731fd1 -->
		<!-- Copyright 2008-2012 WebFilings LLC. All Rights Reserved -->
		<title>2012 0806 8-K BAPINEUZUMAB</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s36EE26550DAA724228C3D2EABC122D4A"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):   August 2, 2012</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="jjlogo.gif" style="height:62px;width:241px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="31%"></td><td width="38%"></td><td width="31%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;&#160;08933</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)  &#160;(Zip Code)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  732-524-0400</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s36EE26550DAA724228C3D2EABC122D4A"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01&#160;&#160;&#160;&#160;Other Events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">The Company today announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease is being discontinued. Janssen Alzheimer Immunotherapy (Janssen AI), a subsidiary of the Company, is a partner with Pfizer in the Alzheimer's Immunotherapy Program (AIP). The Joint Steering Committee for the AIP has decided to discontinue the development of bapineuzumab IV in mild-to-moderate Alzheimer's disease based on the co-primary clinical endpoints not being met in the Janssen AI-led Studies 301 and 302. Pfizer has issued separate news releases on the top line results of both of these Janssen AI-led studies.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects to record an after-tax, non-cash special item related to in-process research and development</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#32;consisting of a net charge to earnings of between $300 and $400 million in the third quarter of 2012 related to the discontinuation of the phase 3 clinical development of bapineuzumab IV in mild-to-moderate Alzheimer's diseas</font><font style="font-family:inherit;font-size:11pt;color:#333333;">e.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated August 6, 2012 is attached as Exhibit 99.1 to this Report.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release dated August 6, 2012.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="49%"></td><td width="5%"></td><td width="21%"></td><td width="25%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 6, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lacey P. Elberg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lacey P. Elberg</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assistant Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a201208068-kex99bapineuzum.htm
<DESCRIPTION>2012 0806 8-K EX 99 BAPINEUZUMAB IV
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings e731fd1 -->
		<!-- Copyright 2008-2012 WebFilings LLC. All Rights Reserved -->
		<title>2012 0806 8-K Ex 99 BAPINEUZUMAB </title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sAA1396F00B25C5C8DAB1D32CA6BF8AB9"></a><div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:center;"><img src="jjlogo.gif" style="height:62px;width:241px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="44%"></td><td width="7%"></td><td width="21%"></td><td width="6%"></td><td width="22%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Media Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Al Wasilewski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ellen Rose</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-1130</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(650)  794-2546</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 447-5918 (M)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(650) 491-4901 (M)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investor Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lesley Fishman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ellen Sipos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-3922</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-3709</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">JOHNSON &amp; JOHNSON ANNOUNCES DISCONTINUATION OF </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PHASE 3 DEVELOPMENT OF BAPINEUZUMAB INTRAVENOUS (IV) IN </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MILD-TO-MODERATE ALZHEIMER'S DISEASE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPANY EXPECTS TO RECORD A CHARGE TO EARNINGS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS A SPECIAL ITEM</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IN THIRD QUARTER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">NEW BRUNSWICK, NJ  </font><font style="font-family:inherit;font-size:10pt;">- (August 6, 2012)  </font><font style="font-family:inherit;font-size:10pt;color:#333333;">Johnson &amp; Johnson (NYSE: JNJ) today announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease is being discontinued.  </font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Janssen Alzheimer Immunotherapy (Janssen AI), a subsidiary of Johnson &amp; Johnson, is a partner with Pfizer in the Alzheimer's Immunotherapy Program (AIP). The Joint Steering Committee for the AIP has decided to discontinue the development of bapineuzumab IV in mild-to-moderate Alzheimer's disease based on the co-primary clinical endpoints not being met in the Janssen AI-led Studies 301 and 302. Pfizer has issued separate news releases on the top line results of both of these Janssen AI-led studies.  </font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">&#8220;While we are disappointed in the results of the two bapineuzumab IV studies, particularly in light of the urgent need for new advancements in Alzheimer's disease, we believe that targeting and clearing beta amyloid remains a promising path to potential clinical benefits for people suffering from this disease,&#8221; said Husseini K. Manji, M.D., Global Therapeutic Area Head for Neuroscience, Janssen Research &amp; Development, LLC. &#8220;Janssen remains strongly committed to tackling the enormous unmet medical needs in Alzheimer's disease. We believe the trial results will provide a rich data set that will advance our understanding of this complex disease and inform future research in this field. Studies with other compounds in earlier stages of development in the AIP portfolio are continuing and future development strategies will be discussed jointly by the alliance partners.&#8221;</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-more-</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sAA1396F00B25C5C8DAB1D32CA6BF8AB9"></a><div></div><br><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-2-</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects to record an after-tax, non-cash special item related to in-process research and development consisting of a net charge to earnings of between $300 and $400 million in the third quarter of 2012 related to the discontinuation of the phase 3 clinical development of bapineuzumab IV in mild-to-moderate Alzheimer's disease.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">About the Bapineuzumab IV Phase 3 Studies</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#32;</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Four placebo-controlled Phase 3 studies comprised the bapineuzumab clinical development program. Janssen AI led the two completed 18-month, Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety studies of patients who are ApoE4 carriers (Study 302) and ApoE4 non-carriers (Study 301). The two co-primary clinical endpoints are change in the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), a validated measure of cognition, and the Disability Assessment for Dementia (DAD), a validated instrument to measure function. </font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">In addition to the Janssen AI-led studies, Pfizer led two primarily ex-North America 18-month, Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety studies of patients with mild-to-moderate Alzheimer's disease who are ApoE4 non-carriers (Study 3000) and carriers (Study 3001). </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">About Bapineuzumab IV</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#32;</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Bapineuzumab IV, an investigational therapy studied for the treatment of mild-to-moderate Alzheimer's disease, is an antibody that targets beta-amyloid (A</font><font style="font-family:Arial;font-size:10pt;color:#333333;">&#223;</font><font style="font-family:inherit;font-size:10pt;color:#333333;">), a protein that can exert toxic effects in the brain and is believed to play a central role in the pathology of Alzheimer's disease. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">About the Alzheimer's Immunotherapy Program</font><font style="font-family:inherit;font-size:10pt;color:#333333;">&#32;(AIP)</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">The Alzheimer's Immunotherapy Program (AIP) of Janssen Alzheimer Immunotherapy and Pfizer Inc. is an equal collaboration committed to researching and developing selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">-more-</font></div><br><div></div><hr style="page-break-after:always"><a name="sAA1396F00B25C5C8DAB1D32CA6BF8AB9"></a><div></div><br><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">-3-</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">We believe it may be possible to reduce the burden of disease through early intervention in the illness. The AIP is dedicated to delivering comprehensive and integrated solutions that help address the needs of people impacted by Alzheimer's disease. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;font-weight:bold;">About Johnson &amp; Johnson</font></div><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Caring for the world, one person at a time&#8230;inspires and unites the people of Johnson &amp; Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 250 Johnson &amp; Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.&#160; The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.&#160; If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &amp; Johnson.&#160; Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &amp; Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012.&#160; Copies of this Form 10-K, as well as subsequent filings, are available online at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.investor.jnj.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or on request from Johnson &amp; Johnson.&#160; Johnson &amp; Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"># # #</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>jjlogo.gif
<DESCRIPTION>JOHNSON & JOHNSON LOGO
<TEXT>
begin 644 jjlogo.gif
M1TE&.#EAM0`O`/<``)H<*8\S/HT\.YDC*9@J-9@X)I8U.ZD:'K<-#K@,&;@5
M&ZL:)ZD<-+H:)[@9,JDB'ZDE**8H-J,T/*<Z-:\R-:XT/*X\,:L\.;0D([0B
M+;,K*KDC)+PC+;PN++<G-K<S.I@Y2*4L0:@X1[HM1;@W1KPX5;-$-H]#38]/
M4)5"0))#2)E`1IY!5)153)=26J9%2*E+4Z=26K=#2+=&5;%23K=46*148;M+
M8;E99ZIE9ZQP<+=D;+YB:[]K:+IR:+1R<\H*&LH5&M$.%M0/&MH(%=T.'=$6
M#]45&\H*(L,2),83*\0;),(;+,L3(\H3+,H:(\H;*\D;,]@))M4)-M87)M,8
M-L,B*L(I+,PC(\HC*\4G-\DR)\DS.],C*M<E-],R-^42&>85)N85-_,<,>,C
M+>8I.NHQ+O$A+_\[/,4;0\8I1<<V1L([5-@G1-DM4-HY1]8Q4-,_5=P^5^,J
M1.@W2.`\5_\S3/<Y5\%$2\=+4\%,6\M!4,Q&6LI,5,Q)6LE56]E$2-A+5]U<
M7<I)8<979-A(8M5:9]%<=]M4=-M><-!E7<IG:,MG=L-T<\)U?,%\?,MQ<,]R
M?,]Z=\A\?M9E:-9H==9U>.9`0.1%6>I36OQ#2?5,7_A/5N=9:>-><O)+:?U7
M:?Y7<^1I:.=H=^9S<.1S>^%_?/)B;/IH=O!Q:_]S=?YT?+1]@,MX@\-]E=5I
M@-MWA.%OB.=VA?UD@/UM@O]OCOUWAOU\D\&`?J^2CLB'A\R4E\N;F=:"B-N,
ME-J7F-JCFM6DIM2PLN>&B>N'E.23AN>6F/B(B_V(EOV2BON6F.6;I?J)H?V9
MI?^=LNJADOJKGNFEI^:JMNBTJOBFJ?ZHM/RTK/ZVN?^LQ/VXQ?^\TNK!N_[#
MNO;&Q/_#P__#RO_*QO[*R__)U?_0Q__4S?[8V?_*X?_;Y?_>\/_CV__RWNCN
M[.SWZ^O\]_/K[/_CY/_DZ_[KY/[KZ__D\__E^O[L\__L^OWTZ_3V]/3U^O3]
M]/3^_?[S\_[T^_W[]/[^_BP`````M0`O`$<(_P#_"1Q(\-^^@P43*D1H\.`^
M@0P52IQ(L:+%BA$;0GQXL:/'CP7Q"?3WCV1)C"7]J03)LN7$?OU.CA08$Z)"
ME?[N<:SILB?(?N$\.#`'[UH60/(6"N27$QZ)!K:0Z:GWCY]`=@=KFBRI[U_,
MF/O:\:QJD*!*JPV[BOR7;VF[@C'C67(PRQZ].U&HW;NWE>Q`?^F>9:$B3L2U
MF.W:<91)L"M!M&];CI6XN.2]N;3DE0,2ALNU>,F.'"DG4%ZZ`M/NO<O0!%6$
M;.^>@A)G@%LZ3E3HH.KU;I4"#N*0$4IG38H86^?>R:B"R9Z]?_>0K;G'#YL#
M)[8BB`/W((LM>?SD\?^(\ND;+"U>UI0KETU*FW/U.CW!0$D>O"Y!CJ7+J:X8
MC7?Q'$/%&*@P4@\U01#6B@[Q7'-`%JA\$`XX&"R!BC@@1)..)D<T`-\U3CCA
M#4GVG"/"+_*\T\<1:&!R"SR5!+%%//S4N%!E_O`32R7WQ),-`=)095)E/A5I
MI%<8AG./>#/,4Q-:1T8I957U,#7EE5+6R%=?6'8)4D9>AAFE0QN):29E'*E4
M3R\&7"-.!.$L51"13FEQ#@B^5'EFD:J)4,DYK3@"3U(V#:15=!XHTPP(>NY9
M9'P-+&*?+**5PX\]VO#AP2+7>("*!\W,,T\U40!Q3#SQ=-*`![`(!,\Q"EC_
M@4.5U3@0!03R^"./.`#,4,Y>U9``A0+0^&!"*A^(D\T,'BQ``3?\S*-&%5HT
M0U5*CNV58S8>/'"-/.=0084I\=@S#S(1&"".''5T(L,Y\)CSB115O'-/-FH$
M<<4[_=23#1RW7K.D'PTTH$Q2\BP2P37JW'-.(<,J`@X$J%B@3#FRC."`%8+<
M4P\S:52Q!CR%_I503CG6,\@GMC10B9/]R!..#!FL44HY7_7S`PPX>[7+"\I<
MRT\U*4QC53_?R*"'."6]$P,(O3#%3D[#D!#!#,90)U`Y*.0`#TSW_'+U.57A
M!-X]P`2#5HW6<%%-!A"(\U4YQT10`2'4H.4O"]58_YG.'S*$8Q4_Y\3`"#HP
MR?/("\U\/<\R(.``SUGW@$-(!'Z2HPX[7BTC0C9,^7,.#"+XPI1C%?FS#`&_
MIJ/N9(Z>Z4]LF=T#BR5\C>0/ZK'W[OOO)P,O_/#$HU2\F&$1>1&9QW?$D?()
M*<]\\Q8YI!(\XO!P@C!04J1K-3M$8R/U-U;%3SW+/#W/13F50PPC[WA%_D#0
M\R..`VNHHTX@6A!*_V(P.9\C/%4.`D0C=V!J7HX\X8%KI,,9#CC@[BA3$G%$
MH0KD,,8+_#<_W0VD'J6`P"+@48]A4"$+\1-(/7*RE[TL!1X4:``=""$/>6AK
M(-'*U4!0M15^W#!'50'/.__``Z5ZS*.(5>+'DQCCCX><8P`9`!T\&K"$K%GE
M+#;4&E/B@0SCD$`OJ@'/0-Y1HZ.QT'_]@`<_PE(5Y]3#B/78DA++2!(EOE$C
M%N%',Z)`@G/<`T%':`8U"("*(E!!'OW(!B,T`($:4$,<6F@`,LHA`V5X00J@
MF$<]:G`,301A#>=`AB=0`04(G$,>G8J"%.[@@5*<8Q1,6$4][&$,&;Q!"]Z0
M!P0Y\,@1D$J2H?-'/08%CV8,`!;O>,<%,*",\ZTA"&\0QR`*,8<$4.,=YX"%
M#"Y`@&-<0T!->$<T<-",(P0A'4/S90.TH`QQ5(`:5J#"*H98B#(480B@(($X
MM"'_!2C\2AR'B(,'+'&.<P#B"&8H1R5D08LP=(&,'6%A-B(PBF9(@0JC$"(7
M@.`%6V@#&9MZXSD\@`0FG,-<'VB"%V"0*WD(8@E1^(X\5I$`)>P!1=58`S.T
M4`D;4F,)5*C6-40!`67$XQ[7:``0M)".>Y#C`&&X@QJ88<-J,"($`/#`!_+0
MC&[<(QPU($$V[$`%")3#.;:(0A+>4(UF=,(#XG@C,:8@!EF0D!I'"(,#JI&3
M;$1!"6H`4#@R`(0YC$`<Y0":%@9`CAY]@0P-0$4VFF$%I/1C'GRXZ##D`4(@
MC"$4(G@'E[B$PWJT0A?IN`8$7D$/JQPD)TH42&2\TH^<_]#6'FUQ53]<6S8Q
MCD1K\CM)/^@Q%IB0I2M,42)8%K,5?\#$'"DHQSLN)SB$Q(PI8'D+"R<H/Y.@
MA2?M8"%!.+@3X\:DCJ49B#M@`CN*V$\$XMA+,TKPG`Y&21Z5,`1?W@&#O)V7
MM/9MB3_N-P4WA!;``6:)KCK1AB@P(&LD@5Z"C3?AWJVDPE*2,(:/=.&$Z(-W
M&_Y2B(FGX0`G<,1G@EZ)$WQB%!^)>2UV\?)6/)$8RY@@"61>>SO($.K4J!X<
MK(B/DX)@ZNTCMSXLXS^N95SEP?9L:YDP0QY2(V/,H!J54-M%]$@"600@&[NM
M\-3N48X81"(;(G#21IP\NQGPP?\0+K!*E"N<(W1=$QD,(%N'2Z;$I(+B'#7(
MDVMI##S"B6`&!7V!+K2VW)/%8PU1^$8STER6^2DO9H2(PBWBD0X.<.$>(UG,
M3J@4@PRLHAH2*,=6;%QH;SA`#35$15[XPCG8/02I54!".1HQB6L%6"4<J8<R
M(/"N>33C"5_0R=H&`FKHJ`8`6K#%&AHW1U`_!"87UI9(C*N/:R^E)CSA2\RN
M\EOO&NHQ\;@`!YIAKC8X02\=+NY>BI&$,@C'MUD9R='ZX0Z<R&DCZZ`)3283
M;IH0"L0F^R!1(<%965#A"4F!R>-:8(U%U*!O(LT`%1KPC7240Q("B-,^PE,*
M"02C-,C_$`$N",4/5FRC1SER7PU:,(X>]$!P_<CF#!S!67LLZP4].YD_WO*-
M#T#@&H1;PA.,H=QZE",'/_!&#'1A*7[``QEBD((L4D0-&5#"1D,3`0S(V(\R
M`_UHXK#!"O71+RROH!FPJ`$PFHI*'+S`&BJ91RM"T(Q&5X0?J&A`#6JHC"`<
MX5OBF$$3J'"-<HR@%IOP`#)NH(8D4,$6Q-&"N%!1CWZ(XP!DH$*3X#$#+U"!
M`[^2AR&TL-==$\(65"A#.:@Q`64`8@TBN`4RM,!,>!!C#E)P`C*NZ&]^4,,'
MX=`,`#!PC7J<`PI4$`4VS],`0YPC%&X`*24J00(M2&$.\2A'_Z;#@(!?U:,2
M59`"!XQJC#<@H374R48#G@`(XDC@%F2U!CGP@`I5:``/?N`,;R`$E[`>)9!^
M7N`DN14]9E$.0I$-\F`-05`$F+`PQP`&9!`__5(.)@`-\7`.&;`$JW`,E%`.
M'T`%J'`.&E0.FD`%@/`-8J4*#:`!ZT$(R-!%4H`<[_`"4&$/,%%,'K`DU>`!
M#=`,J$`+WX`!&W`,6Q(.E2`".=`+V;`&?W`.Z4`*#7`*LQ0(*L4%B2`.98`%
M1@5DZ3`,,E`.`7($9%`.*B`.S1`$02!=+U`-UX`!DH0*J^`-&Q`$J``/U"!6
M9Q`&56`.QE8%2<`7=G$.;&`,*8('1O^`!M4@`N5`"4>`!3128V9!9B.@'NE`
M!D6`"O;"#0F"#/`P#Q%8`$T%#QK7!'9U#A60!:`0",1P#^F0">+B`>60#K:0
M!0TP4=E`25Z`!(8P1)3`42=50Y1`"4*H>5JP6>4``4&`#.+@`O+@"PX`!]5P
M#K8`!1XP"HLP`U$0!<0`#[:P!!#05.>`"53P`4-$BR\`">GP#LH@!5*@3_70
M#%1`!,X``DT5#AR0!%IP#._PC$^`"J/`"/)0#%_0!0VD&5#0!,-`(_50#1'P
M#?;1!T-P!*`$(UV`!>G`"[G`/OH@A!'0!F4`!91`%4/3`%[@!%'@`3+P#3XX
M#P,0;>92#S/_4##?4"/R0`D+T$?A<0P.H`5ZP!?*L`:ND3<Y00FQH@4'($(T
M<@_>,`!<@`RY$@\0X`1SP`;HX$-+`@\%I0P\D"M\40YKT`1B4`40(),EX@=,
M\)+-(@MOU`_+D`9J(`XU0@T*@%'GD!/AP`#1)D01$`4-@`WS``\&@`P?,'A[
M<0T*L$X-D`$=@'27<@-1H`6J)@_#$(QJT`Q68A8W$7,S$!P>@`,^&!-+\@[P
M$#^+043?!0_/816<Y5M5,41Z`AY)Q&SW4(J=!Q:T%5NU%1Z^Y@]3$TQPL0BB
M4`Y6\PU4\1##-$16H1A>X4--I`_AH4.#(P_.<2C\`A/.X8-^L63SYH`.<52=
MYZ-&,O%&068RRN-\('!4$P4+1V00B3%;]+D5N?,5E28_UG-A/#$]E49P,=%M
M,U$F".<5]N`*NA`/\(`#$="7-39R.$&@<Y(2:[8/N5.@`G&@.%006[%C]),0
M\C`#S;`7U!`"I!%<-S81>C0#3`$/AM-Y,T%H+N8/UR`"?G0/E8`,(+JB?\$/
M;&`+>R$.K&,2>^:C"G$/T1`"V%`.C]`*Y]"C2*HK:X`)Y_`-ZI*A2&H1.8((
M:5`(VM`]6WH30\,`:H`,*Q1A8QJB%,%J:VH0^M`.'/JF=%JG=OIK$U%D&Q80
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
